Pharmacodynamic efffects of natalizumab on integrins such LFA-1 (CD11a), or chemokine receptors (CCR6, CXCR3) in multiple sclerosis patients.

Trial Profile

Pharmacodynamic efffects of natalizumab on integrins such LFA-1 (CD11a), or chemokine receptors (CCR6, CXCR3) in multiple sclerosis patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top